Wednesday, July 22, 2020 4:21:47 AM
Recent OGEN News
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion • Business Wire • 03/18/2024 11:00:00 AM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 03/06/2024 09:24:29 PM
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion • Business Wire • 03/05/2024 12:45:00 PM
- Oragenics Announces Closing of Public Offering • Business Wire • 03/01/2024 09:04:00 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/29/2024 09:41:14 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/28/2024 02:03:04 PM
- Oragenics Announces Pricing of Public Offering • Business Wire • 02/28/2024 02:25:00 AM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 02/27/2024 10:09:12 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 02/27/2024 10:04:34 PM
- Oragenics Announces Proposed Public Offering • Business Wire • 02/27/2024 09:33:00 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/13/2024 01:06:23 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/12/2024 09:45:18 PM
- Oragenics, Inc. Announces Leadership Transition • Business Wire • 02/12/2024 09:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/07/2024 01:00:18 PM
- Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement Agreement • Business Wire • 02/07/2024 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/05/2024 01:00:23 PM
- Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion • Business Wire • 02/05/2024 01:00:00 PM
- Oragenics Announces Termination of At-The-Market Offering Program • Business Wire • 01/23/2024 10:34:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 10:18:59 PM
- Form 5 - Annual statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/22/2024 10:30:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/16/2024 02:10:51 PM
- Form FWP - Filing under Securities Act Rules 163/433 of free writing prospectuses • Edgar (US Regulatory) • 01/16/2024 02:08:13 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 01/16/2024 02:04:40 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/10/2024 09:37:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/02/2024 10:09:29 PM
Endexx Corporation (EDXC) Leverages Global Market Trends and Legislative Reforms to Spearhead Growth in the Cannabis and Plant-Based Wellness Sectors • EDXC • Mar 27, 2024 3:01 PM
Applied UV, Inc. Announces Pricing of $2.76 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules • AUVI • Mar 27, 2024 2:51 PM
POET and MultiLane Collaborate to Develop High-Speed Pluggable Transceivers for AI Networks • POET • Mar 27, 2024 10:52 AM
Maybacks Global Entertainment Opens 23 More Stations in Important Major Cities • AHRO • Mar 27, 2024 9:00 AM
NxGen Brands Inc. Forecast to Deliver 140% Growth in Q1 2024 • NXGB • Mar 27, 2024 7:30 AM
Kona Gold Beverages, Inc. Strategic Advancements: Covert LLC Introduces Federally Legal D9 Gummies and Revamps Innovative eCommerce Platform, Propelling Toward $12 Million Annual Revenue Goal • KGKG • Mar 26, 2024 8:30 AM